Original Article | Published:

Antidepressant treatment of premature ejaculation: discontinuation rates and prevalence of side effects for dapoxetine and paroxetine in a naturalistic setting

International Journal of Impotence Research volume 27, pages 7580 (2015) | Download Citation

Abstract

The present study aimed to investigate prevalence of and reasons for selective serotonin reuptake inhibitor (SSRI) discontinuation, and compare the two most common SSRIs used in premature ejaculation (PE) treatment, in naturalistic settings (that is, outside clinical trials). The sample consisted of 132 Finnish men with a mean age of 42.5 years (s.d.=10.6) who had received medical treatment for lifelong PE. The men were enlisted for the study after identifying individuals from the third author’s (a physician specializing in sexual medicine) patient registry. Participants responded to a secure, online questionnaire. PE treatment-related side effects of, and discontinuation rates for, different SSRIs were retrospectively self-reported. Treatment efficacy and happiness with treatment were retrospectively self-assessed. Discontinuation rates were uniformly high, ranging from 28.8 to 70.6% between different SSRIs. Dapoxetine was associated with the highest dropout rates (70.6%), and paroxetine the lowest, discontinuation rates. Limited efficacy and side effects were the most common reasons for discontinuation. Paroxetine was more effective and better tolerated than dapoxetine. A considerable number of patients chose to spontaneously discontinue treatment, especially so in the case of dapoxetine, corroborating recent studies conducted in naturalistic settings. Further research efforts are necessary to develop new and improve existing PE treatment alternatives.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    . Prevalence of premature ejaculation: a global and regional perspective. J Sex Med 2005; 2: 96–102.

  2. 2.

    , , , , , . Psychosocial interventions for premature ejaculation. Cochrane Database Syst Rev 2011; 10: CD008195.

  3. 3.

    , . The role of local anaesthetics in premature ejaculation. Br J Urol Int 2012; 110: E943–E948.

  4. 4.

    , , , , , , . Acupuncture versus paroxetine for the treatment of premature ejaculation: a randomized, placebo-controlled clinical trial. Eur Urol 2011; 59: 765–771.

  5. 5.

    , . Oral agents for the treatment of premature ejaculation: review of efficacy and safety in the context of the recent International Society for Sexual Medicine criteria for lifelong premature ejaculation. J Sex Med 2011; 8: 2707–2725.

  6. 6.

    , . Dapoxetine: an evidence-based review of its effectiveness in treatment of premature ejaculation. Core Evid 2012; 7: 1–14.

  7. 7.

    , , , . Relevance of methodological design for the interpretation of efficacy of drug treatment of premature ejaculation: a systematic review and meta-analysis. Int J Impot Res 2004; 16: 369–381.

  8. 8.

    , . Pharmacogenetics of SSRIs and sexual dysfunction. Pharmaceuticals 2010; 3: 3614–3628.

  9. 9.

    , , , . Primum non nocere: an evolutionary analysis of whether antidepressants do more harm than good. Front Psychol 2012; 3: 117.

  10. 10.

    , , , , . Dapoxetine for the treatment of premature ejaculation: Results from a randomised, double-blind, placebo-controlled phase 3 trial in 22 countries. Eur Urol 2009; 55: 957–968.

  11. 11.

    , , , , , et al. International Society for Sexual Medicine’s guidelines for the diagnosis and treatment of premature ejaculation. J Sex Med 2010; 7: 2947–2969.

  12. 12.

    , . Utility of selective serotonin reuptake inhibitors in premature ejaculation. Curr Opin Investig Drugs 2004; 5: 743–747.

  13. 13.

    , , , , , et al. Treatment of premature ejaculation in the Asia-Pacific region: results from a phase III double-blind, parallel-group study of dapoxetine. J Sex Med 2010; 7: 256–268.

  14. 14.

    , , , , , . Dapoxetine treatment in patients with lifelong premature ejaculation: the reasons of a “Waterloo”. Urol 2013; 82: 620–624.

  15. 15.

    , , , , , et al. Acceptance of and discontinuation rate from paroxetine treatment in patients with lifelong premature ejaculation. J Sex Med 2009; 6: 2868–2877.

  16. 16.

    , , . Validation of three early ejaculation diagnostic tools: A composite measure is accurate and more adequate for diagnosis by updated diagnostic criteria. PLoS ONE 2013; 8: E77676.

  17. 17.

    , , , , , et al. Discontinuation of use and switching of antidepressants: influence of patient-physician communication. JAMA 2002; 288: 1403–1409.

  18. 18.

    , , , , . Persistence, switching, and discontinuation rates among patients receiving sertraline, paroxetine, and citalopram. Pharmacotherapy 2005; 25: 660–667.

  19. 19.

    , . Why don’t patients take their medicine? Reasons and solutions in psychiatry. Adv Psychiatr Treat 2007; 13: 336–346.

  20. 20.

    . Dapoxetine: a new option in the medical management of premature ejaculation. Ther Adv Urol 2012; 4: 233–251.

  21. 21.

    , , , , , et al. Efficacy and tolerability of dapoxetine in treatment of premature ejaculation: an integrated analysis of two double-blind, randomised controlled trials. Lancet 2006; 368: 929–937.

  22. 22.

    , , , . Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 2003; 326: 1167.

  23. 23.

    , . Premature ejaculation and pharmaceutical company-based medicine: the dapoxetine case. J Sex Med 2008; 5: 966–997.

  24. 24.

    , . Paroxetine: current status in psychiatry. Expert Rev Neurother 2007; 7: 107–120.

  25. 25.

    , , . Genetic and environmental influences on sexual orientation and its correlates in an Australian twin sample. J Pers Soc Psychol 2000; 78: 524–536.

  26. 26.

    , , , , , . The Premature Ejaculation Profile: Validation of self-reported outcome measures for research and practice. BJU Int 2009; 103: 358–364.

Download references

Acknowledgements

This research was funded by Grant No. 138291, a personal post-doctoral research grant awarded to the first author, from the Academy of Finland. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Author information

Affiliations

  1. Department of Behavioural Sciences and Philosophy, University of Turku, Turku, Finland

    • P Jern
  2. Genetic Epidemiology Laboratory, QIMR Berghofer Medical Research Institute, Herston, QLD, Australia

    • P Jern
  3. Department of Psychology and Logopedics, Abo Akademi University, Turku, Finland

    • A Johansson
    •  & P Santtila
  4. Department of Pharmacology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

    • A Johansson
    •  & L Westberg
  5. Medical Centre Mehilainen, Turku, Finland

    • J Piha

Authors

  1. Search for P Jern in:

  2. Search for A Johansson in:

  3. Search for J Piha in:

  4. Search for L Westberg in:

  5. Search for P Santtila in:

Competing interests

During the past 3 years, the third author (Dr Piha) has received financial compensation from Eli Lilly (lecturer, conducting scientific studies), Janssen-Cilag (conducting scientific studies), PharmaNord (lecturer, consultant) and MEDA (lecturer, consultant). None of the aforementioned have had any role in the present study, including data collection, preparation or analysis.

Corresponding author

Correspondence to P Jern.

About this article

Publication history

Received

Revised

Accepted

Published

DOI

https://doi.org/10.1038/ijir.2014.37

Further reading